Abstract:2531 Background: TST005 is a novel bi-functional fusion protein combining a high affinity PD-L1 mAb and a differentiated TGF-β trap with improved stability. In pre-clinical study, TST005 showed no antibody-dependent dependent cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) activity. Methods: This is a Phase 1, dose escalation study with classic 3+3 design to evaluate the safety, tolerability, PK and pharmacodynamic and preliminary anti-tumor activity of TST005 and determine the maximum tolerated dose and/or the Recommended Phase 2 Dose (RP2D). Eligible solid tumor patients who have failed prior standard therapy(ies) and have received no more than one prior immune checkpoint inhibitor (ICI) treatment will be enrolled to receive TST005 intravenous (IV) infusion every 3 weeks until disease progression assessed by the Investigator per RECIST v1.1 and/or immune RECIST, or unacceptable toxicity. Results: The study is ongoing at 4 clinical centers in US and China. As of 31 Jan 2023, 18 eligible subjects have been enrolled into different TST005 dose levels: 2 at dose of 1mg/kg, 4 at 3 mg/kg, 4 at 10 mg/kg, 3 at 20 mg/kg, and 5 at the last dose level of 30 mg/kg. The enrollment is still ongoing. No DLT was observed so far. The most common treatment-emergent adverse events (TEAEs) ( > 10%) included: fatigue (38.9%), rash (22.2%), anemia (16.7%), myalgia (16.7%), and arthralgia, dehydration diarrhea, dry skin, hematuria, hypokalemia, pruritus, lymphocyte count decreased were 11.1%. 7 patients (38.9%) experienced ≥Grade 3 (G3) TEAEs according to CTCAE V5.0, 1 of whom were considered as related to TST005: it was an infusion related reaction (G3), and caused discontinuation of treatment. Two subjects experienced IRRs (G2 and G3 respectively), both at the dose of 3mg/kg cohort. One subject of 30mg/kg dose cohort presented a squamous cell carcinoma of skin, which is known as a classic side effect of TGF-β directed therapies. The subject was discontinued from study and to receive resection. No treatment-related deaths occurred. TST005 demonstrated a nonlinear PK profile between 1 to 20 mg/kg with calculated t1/2 of 4-9 days. ADA was observed in most ADA evaluable subjects, PK at doses ≥ 10mg/kg were not impacted by ADA. At 20mg/kg, the receptor occupancy increased to > 90% immediately after infusion and remain at this level up to C2D1. Start from 1mg/kg, serum TGF-β1 was depleted immediately after dosing, sustained to next dose of TST005. 11 subjects had at least one post treatment tumor assessment per RECIST 1.1. 7 subjects (63.6%) had best overall response of SD. No PR or CR had been observed. Conclusions: TST005 monotherapy demonstrated a good safety and tolerability, nonlinear PK characteristics and significant target engagement in patients with advanced solid tumors. Continue investigation of TST005 as monotherapy or in combination with other therapies are warranted. Clinical trial information: NCT04958434 .

Preclinical And Translational Pharmacokinetics Of A Novel Thiomab (Tm) Antibody-Antibiotic Conjugate Against Staphylococcus Aureus

Pharmacokinetics and Pharmacodynamics of DSTA4637A: A Novel THIOMAB™ Antibody Antibiotic Conjugate Against Staphylococcus Aureus in Mice.

Sustained Activity Of Novel Thiomab Antibody-Antibiotic Conjugate Against Staphylococcus Aureus In A Mouse Model: Longitudinal Pharmacodynamic Assessment By Bioluminescence Imaging

Implementation of Systematic Bioanalysis of Antibody-Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats

Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase

Quantification for Antibody-Conjugated Drug in Trastuzumab Emtansine and Application to In Vitro Linker Stability and In Vivo Pharmacokinetic Study in Rat Using an Immuno-Affinity Capture Liquid Chromatography-Mass Spectrometric Method

A Phase 1, First-in-human, Open-Label, Dose Escalation and Dose Expansion Study of TST005 in Patients with Locally Advanced or Metastatic Solid Tumors

Novel antibody-antibiotic conjugate using KRM-1657 as payload eliminates intracellular MRSA in vitro and in vivo

Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics

A High-Affinity Native Human Antibody Disrupts Biofilm from Staphylococcus aureus Bacteria and Potentiates Antibiotic Efficacy in a Mouse Implant Infection Model

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease

Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4

Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors

Abstract 2793: Preclinical pharmacokinetics in cynomolgus monkeys and first in human dose prediction of DB-1303, a HER2-targeting antibody-drug conjugate

Preclinical Evaluation of STI-8811, a Novel Antibody Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma

Development and validation of pharmacokinetics assays for a novel HER2-targeting antibody-drug conjugate (SHR-A1201): Application to its dose-escalation pharmacokinetic study

Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus infections

P911 Development and Characterization of SPY002, a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting TL1A for the Treatment of IBD

Mechanism of Action for an All-in-One Monoclonal Antibody Against Staphylococcus Aureus Infection.